Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Objective: To estimate the incremental cost of implementing policies for more intensive control of blood glucose concentration and blood pressure for all patients with type 2 diabetes in England. Design: Extrapolation of resource use and cost data derived from a randomised controlled trial. Setting: General practice, outpatient care, and inpatient care. Population: Trial population with diagnosed type 2 diabetes in England extrapolated to the population of England. Main outcome measures: Total costs based on use of healthcare resources including costs of management, treatment, and hospitalisation. Results: The incremental net annual cost of implementing more intensive control of blood glucose and blood pressure to all people with diagnosed type 2 diabetes in England is estimated to be £100.5m ($156m; C159m), which is equivalent to less than 1% of the proposed additional annual expenditure on the NHS in 2001-5. This estimate varied in sensitivity analyses from £67m to £121m. Conclusions: Policies to improve control of blood glucose and blood pressure of people with type 2 diabetes are effective in reducing complications associated with the disease and are also cost effective. The total cost represents a small fraction of the NHS's spending plans.


Journal article


British Medical Journal

Publication Date





860 - 863